September 26, 2017 7:48am
It has been worse, be ready as I stated turn, turn and turn after churn, churn and burn
I’d be a buyer of some equities – the oversold shall rise again while some overbought will tag along
Preview RMi's morning call. You’d be reading this if you were a SUBSCRIBER!
Pre-open indications: 3 BUY and 3 SELLs
If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know when to get in and out or get back in again!
It’s called premium content for a reason: I report the truth in “our” universe!
A critical pre-market indication ahead of “our” universe’s open!
Lower to mixed open expected
Dow futures are FLAT 0.00% (1 point) and NASDAQ futures are UP +0.20% (12 points)
U.S. stock futures on Tuesday pointed to a mixed yet higher open, as the Dow look set to stabilize after three down sessions in a row.
European stocks edged slightly lower on rising tensions between North Korea and the United States.
Asian markets were pressured, following declines from the overnight, as the war of words between North Korea and the U.S. escalated.
Data docket: A July figure for a U.S. home price index is due at 9 a.m. Eastern Time, then August data on new home sales is expected at 10 a.m. ET. Economists polled forecast that 585,000 new homes were sold. Also at 10 a.m. ET, a September number for a consumer confidence index is slated to arrive, with economists anticipating a reading of 119.5.
Issues that affect the trading day: Investors are waiting for fresh readings on the housing market and consumer confidence, as well as speeches from Federal Reserve chief Janet Yellen and three other U.S. central bankers.
The cell therapy sector closed NEGATIVE on Monday, Friday, Thursday, Wednesday and last Tuesday.
The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):
· Monday closed NEGATIVE with 23 decliners, 16 advancers and 4 flats;
· Friday closed NEGATIVE with 20 decliners, 18 advancers and 5 flat;
· Thursday closed NEGATIVE with 21 decliners, 16 advancers and 6 flats;
· Wednesday closed NEGATIVE with 23 decliners, 19 advancers and 1 flat;
· Last Tuesday closed NEGATIVE with 21 decliners, 19 advancers and 3 slats;
Henry ’omics:
From Tuesday night’s closing bell post “…be careful for the upside you’ve wished for…! The sector is nervous and unsure within “this” market.”
Reiterating, “Cell, stem and gene therapy companies moved to the downside again on what – an algorithmic computation.”
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed up +0.44% on Monday and is NOT indicating in Tuesday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Monday up +0.35% and is NOT indicating in Tuesday’s pre-market%;
- The Health Care Select Sector SPDR ETF (XLV) closed down -0.28% on Monday and NOT indicating in Tuesday’s pre-open;
- The iShares Russell 2000 (IWM) closed up +0.16% on Monday and is indicating a NEGATIVE -0.16% in Tuesday’s pre-open
Companies in my headlights – my six (6), some days one jusy looks to the indexes:
Capricor (CAPR) closed up +$0.03 to $2.17 with 2.52 M shares traded <3 month average = 2.13 M shares>. The aftermarket indication is NEGATIVE -$0.09 or -4.21% - SELL;
Cellectis SA (CLLS) closed down -$0.11 to $27.70 with only 79.27 K shares traded <3 month average = 204 K shares>. The aftermarket indication is a negative -$0.26 or -0.93% - SELL;
Juno Therapeutics (JUNO) closed down -#2.81 to $42.33 with 2.96 M shares traded <3 month average = 2.74 M shares>. The aftermarket indication is a positive +$0.25 or +0.59% - BUY;
BioLife Solutions (BLFS) closed down -$0.11 to $5.28 with 196 K shares traded <3 month average =174.45 K shares>. The aftermarket indication is a negative -$0.18 or -3.41% - SELL;
Verastem (VSTM) closed up +$0.06 to $4.82 with 930.6 K shares traded <3 month average = 1.67 M shares>. The aftermarket indication is a positive +$0.04 or +0.84 – BUY
Pluristem (PSTI) closed flat at $1.54 with 43.35 K shares traded <3 month average =347.6 K shares>. The aftermarket indication is a positive +$0.05 or +3.25% - BUY
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
